The announcement of topline data from Phase 1/2 trials is a significant event for Inozyme Pharma and its investors. Positive results could lead to increased investor confidence and a potential rise in stock price due to the progress towards bringing a new treatment to market. Conversely, negative results could have the opposite effect. The scheduled conference call and webcast with key opinion leaders further emphasize the importance of this announcement, indicating a high level of confidence from the company in their data.